7 min read
Monthly FDA Guidance and Regulatory News Review - April 2026
This April 2026 regulatory update highlights new policies on biomarker validation, expanded access to investigational...
1 min read
Meet Veristat at the Virtual event taking place 26-28 October 2020.
We understand how high the stakes are with gene therapy programs, and that nothing is standard about the study design, study conduct or regulatory process. Join us at the 4th Annual Gene Therapy for Rare Disorders Europe to learn about the manufacturing, clinical, and commercialization challenges drug developers face when bringing gene therapies to market.
Veristat Events:
Attend our Presentation on Gene Therapy Trials:
Join to hear Veristat discuss our gene therapy expertise across the clinical development pathway including how we:
- Built a road map to market for cell and gene therapies, including a central site model and novel clinical trial designs.
- Collaborated with global regulatory agencies to ensure full buy-in on pathways for regulatory approval
- Utilized Long-Term Follow-Up studies to support safety and efficacy data during and beyond approval
.
"Gene Therapy: How we Changed the Paradigm |Case studies from Advanced Therapy Trials"
October 27, 2020 at 12:00 PM GMT
Speaker: Rachel Smith, Project Director, Veristat
Attend our Panel Discussion on Rare Diseases:
Veristat joins the discussion covering how to choose the most suitable comparator, utilize natural history studies effectively, and use appropriate controls.
"Overcoming Hurdles Associated with Clinical Trial Design for Rare Diseases"
October 27, 2020 at 3:00 PM GMT
Host: Mindy Leffler, President & Chairman, Casimir, Panelist: Ewan Campbell, Advanced Therapy & Biotech Director, Veristat
Learn More About the Conference:
Visit the conference website to register or learn more: